However, a subset of luminal BC cell lines exhibited resistance to the effects of the RSL3 tool compound, providing an opportunity to explore mechanisms of RSL3 resistance, as well as an opportunity to identify combination therapies that might prevent the acquisition of resistance to drugs targeting GPX4 or reverse resistance once it occurs. The gene discussed is GPX4; the disease is breast cancer.